0001193125-22-170164.txt : 20220608 0001193125-22-170164.hdr.sgml : 20220608 20220608160110 ACCESSION NUMBER: 0001193125-22-170164 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20220608 DATE AS OF CHANGE: 20220608 EFFECTIVENESS DATE: 20220608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunovant, Inc. CENTRAL INDEX KEY: 0001764013 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 832771572 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-265477 FILM NUMBER: 221003456 BUSINESS ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: 917-580-3099 MAIL ADDRESS: STREET 1: 320 WEST 37TH STREET CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Health Sciences Acquisitions Corp DATE OF NAME CHANGE: 20190108 S-8 1 d342266ds8.htm FORM S-8 Form S-8

As filed with the U.S. Securities and Exchange Commission on June 8, 2022

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

IMMUNOVANT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   83-2771572

(State of incorporation

or organization)

 

(I.R.S. Employer

Identification No.)

320 West 37th Street

New York, NY

  10018
(Address of principal executive office)   (Zip Code)

Immunovant, Inc. 2019 Equity Incentive Plan

(Full title of the plan)

Eva Renee Barnett

Chief Financial Officer

Immunovant, Inc.

320 West 37th Street

New York, NY 10018

(917) 580-3099

(Name, address and telephone number, including area code, of agent for service)

Copies to:

 

Marc Recht

Brandon Fenn

Cooley LLP

500 Boylston Street, 14th Floor

Boston, MA 02116

(617) 937-2300

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 


EXPLANATORY NOTE

We are filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “SEC”) for the purpose of registering an additional 4,659,315 shares of our common stock (“Common Stock”) under the 2019 Equity Incentive Plan, which shares of Common Stock are in addition to the shares of Common Stock registered on our Registration Statements on Form S-8 (File Nos. 333-236665, 333-239537 and 333-262087), filed with the SEC on February 26, 2020, June 29, 2020 and January 10, 2022, respectively (the “Prior Forms S-8”). In accordance with the instructional note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

PART II

 

ITEM 3.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

Pursuant to General Instruction E to Form S-8, the contents of the Prior Forms S-8 are incorporated by reference herein. In addition, the following documents we filed with the SEC are incorporated by reference into this Registration Statement:

 

  (a)

Our Annual Report on Form 10-K for the fiscal year ended March 31, 2022, filed with the SEC on June 8, 2022.

 

  (b)

The description of the Common Stock, which is contained in our Registration Statement on Form 8-A, filed with the SEC on May 9, 2019 (File No. 001-38906) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description.

All documents, reports and definitive proxy or information statements filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


ITEM 8.

EXHIBITS.

 

         

Incorporated by Reference

Exhibit
Number

  

Description

  

Schedule
Form

  

File Number

  

Exhibit

  

Filing Date

4.1

   Amended and Restated Certificate of Incorporation of Immunovant, Inc.    8-K    001-38906    3.1    December 20, 2019

4.2

   Amended and Restated Bylaws of Immunovant, Inc.    8-K    001-38906    3.2    December 20, 2019

5.1*

   Opinion of Cooley LLP.            

23.1*

   Consent of Ernst & Young LLP, independent registered public accounting firm.            

23.3*

   Consent of Cooley LLP (included in Exhibit 5.1).            

24.1*

   Power of Attorney (included on the signature page of this Form S-8).            

99.1

   2019 Equity Incentive Plan.    10-K    001-38906    10.3    June 26, 2020

99.2

   Forms of Option Grant Notices and Option Agreements under 2019 Equity Incentive Plan.    10-K    001-38906    10.3.1    June 26, 2020

99.3

   Forms of Restricted Stock Unit Grant Notices and Award Agreements under 2019 Equity Incentive Plan.    10-K    001-38906    10.3.2    June 26, 2020

107*

   Filing Fee Table            

 

 

*

Filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on this 8th day of June, 2022.

 

IMMUNOVANT, INC.
By:  

/S/ PETER SALZMANN

  Peter Salzmann, M.D., M.B.A.
  Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter Salzmann, M.D. and Eva Renee Barnett, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Title

  

Date

/s/ PETER SALZMANN

Peter Salzmann, M.D., M.B.A.

   Chief Executive Officer and Director
(Principal Executive Officer)
   June 8, 2022

/s/ EVA RENEE BARNETT

Eva Renee Barnett

   Chief Financial Officer
(Principal Financial and Accounting Officer)
   June 8, 2022

/s/ FRANK M. TORTI

Frank M. Torti, M.D.

   Executive Chairperson of the Board of Directors    June 8, 2022

/s/ ANDREW FROMKIN

Andrew Fromkin

   Director    June 8, 2022

/s/ DOUGLAS HUGHES

Douglas Hughes

   Director    June 8, 2022

/s/ GEORGE MIGAUSKY

George Migausky

   Director    June 8, 2022

/s/ ATUL PANDE

Atul Pande, M.D.

   Director    June 8, 2022

/s/ ERIC VENKER

Eric Venker, M.D., Pharm.D.

   Director    June 8, 2022
EX-5.1 2 d342266dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

LOGO

Marc Recht

+1 617 937 2316

mrecht@cooley.com

June 8, 2022

Immunovant, Inc.

320 West 37th Street

New York, NY 10018

Re: Immunovant, Inc. – Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Immunovant, Inc., a Delaware corporation (the “Company”), in connection with the filing of a Registration Statement on Form S-8 (theRegistration Statement”) with the U.S. Securities and Exchange Commission, covering the offering of up to 4,659,315 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), issuable pursuant to the Immunovant, Inc. 2019 Equity Incentive Plan (the “Plan”).

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectus, (b) the Company’s Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, (c) the Plan and (d) originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where due execution and delivery are a prerequisite to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and the related prospectus, will be validly issued, fully paid, and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement.

Cooley LLP 500 Boylston Street, 14th Floor Boston, MA 02116-3736

t: (617) 937-2400 f: (617) 937-2300 cooley.com


LOGO

 

Immunovant, Inc.

June 8, 2022

Page Two

Sincerely,

COOLEY LLP

 

By:  

/s/ Marc Recht

  Marc Recht

 

Cooley LLP 500 Boylston Street, 14th Floor Boston, MA 02116-3736

t: (617) 937-2400 f: (617) 937-2300 cooley.com

EX-23.1 3 d342266dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Immunovant, Inc. 2019 Equity Incentive Plan of our report dated June 8, 2022, with respect to the consolidated financial statements of Immunovant, Inc. included in its Annual Report (Form 10-K) for the year ended March 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Iselin, New Jersey

June 8, 2022

 

1

EX-FILING FEES 4 d342266dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

Form S-8

IMMUNOVANT, INC.

(Exact Name of Registrant as Specified in its Charter)

 

               
Security Type   

Security

Class Title

   Fee
Calculation
Rule(1)
  Amount
Registered
  Proposed
Maximum
Offering
Price Per
Share
 

Maximum
Aggregate

Offering Price

   Fee Rate   

Amount of
Registration

Fee(4)

               
Equity    Common
Stock,
$0.0001
par value
per share
   Other(2)   4,659,315(3)   $4.24(2)   $19,755,496    0.0000927    $1,832
         
Total Offering Amounts     $19,755,496       $1,832
         
Total Fee Offsets          
         
Net Fee Due                 $1,832

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock (“Common Stock”) of Immunovant, Inc. (the “Registrant”) that become issuable under the Registrant’s 2019 Equity Incentive Plan (the “2019 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant’s Common Stock, as applicable.

(2) Estimated in accordance with Rule 457(h) and Rule 457(c) solely for the purpose of calculating the registration fee on the basis of the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Select Market on June 1, 2022.

(3) Represents an automatic annual increase equal to 4% of the of the total number of shares of Common Stock outstanding on March 31, 2022 to the aggregate number of shares of Common Stock reserved for issuance under the 2019 Plan, pursuant to the terms of the 2019 Plan.

(4) The Registrant does not have any fee offsets.

GRAPHIC 5 g342266g0602042323501.jpg GRAPHIC begin 644 g342266g0602042323501.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#V[6MCZ3'M[!E:5\>N%QC]:R]1:Y\>_$ V:R ME;5)&CC/9(EZL/S6UL+=(8E[*.6/J3U)]S6%Y5&^5V1[\J M.%R^G'VT.>I)7MT2/,X?B=KMA.JZOI,?ED\@1O$^/;.1^E>FZ9J$.JZ9;W\ M<13H'4.,$?6IKFV@O(&@N88YH7&&210P/X&HK2UM=(TU+>'$5K;J<;FX1>O4 M]A5QC*+U=T<&*Q&&KP3IT^25^CT:+5%><:O\4U6[-MH=C]KP<>;)G#?[JCG' MNXAN[:.XMY%EAD4,CJ<@@UR'B?XB6.AW#65I%]MO5.'4-A(SZ$]S[#\ZN4 ME%79QT,+6KU/9TXW?];G:45Y7'\4]6MI(WU#146!^ZAT)^A;(->AZ+KEAK]@ M+NPEWIG#JPPR'T(I1J1EHC;%9=B,-'FJ1T[K5'F>M?\ ):+?_KXM_P#T%:]= MKR+6O^2T6_\ U\6__H*UZ7KNN6?A[36OKUCL!VHBC+.W8"LZ;2&!71>%/'-IXDD:TDA-I?J M"?*+9#@==I_I_.K56+=D2V7C'^PM1L$@C M,NQ;@2DY#?<;&.AXSSQSZ5VM5&2EL=>/O \^HSG6=)3== #SH5X+XZ,O^U[=_KURM)^*-_IL? MV/6K%KB2+Y3)GRY![,".3^580E[)\LCW<9AY9I&.)PVLK6E'JCUJN+^*%[+: M>$?+B)7[3.L+D?W<%B/_ !T5@7GQ6N[O_1M'TDB>3A&=C(V?9 .OXUTMQH5Y MXB^'\-CJ#.FI&,2[I>HD!)&?3.<>V:MS4TU$Y*6"G@:U.MBDDN9:7U]?1"?# MG2+2Q\+6UY'&IN;L%Y)<=$\VVA::*0CE2HS MC/H<8K@_#_C"_P#!2MHNM:?,T4;%HQG#ID\XSPRDY/YU+XA\>7/BFW_L71-/ MG'V@[7)YD<>@ Z#U.>E0JD/9\IV3R_&2QWMT_=O?FOI;_AB_\/=6N(/ VLG) M;[ LDL.>WR%L?F"?QJI\*M+M[V\O]5NE6:XA91&7Y*ELDM]>.OUKL?"/A<:) MX8:PNPKS76YKD Y'S#&W\!^N:X"%M6^&6OS%[=KC3;@[=V<+(HY!SV<<\'W^ MM*SCRN6R-%4AB98FEAW:4FK=+I;V]=?O/7KNSM[^UDM;J%)H9!AD<9!KRGP$ M7TCXA7^DQ2,UN3+"A/^-4Y*:..)6$*Y^=F8C [D "DUK_D MM%O_ -?%O_Z"M;WQ'\-7=\;;6M,1Y+JU 5T098J#D,!W(.>/?VJ&FXRMW.ZG M5ITZ^%<]/W=EZV*L7C/Q3!$D47@V=(T 546WE 4#H ,5@2'Q!?>,K/6U\.7M ME(LJ>;Y=M)AN<,3D=U.#6_IWQ:LQ:*NIV%R+I1AC %*L?7!(Q].:N>&/&&M^ M)?$,AAT]$T<##,VA?"S0S::5-J\R_OKL[8\]HP>OXG^ M0HKO+:VBL[6*V@0)#$@1%'8 8%%;PCRQL>)C,3+$UY57U_+H2U5N],L+_'VR MQMKC'3SHE?'YBK5%4GV!)L["UMB>IAA5,_D*MT44!*3D[R= MRO=V%G?H$O+2"X4=%FC#@?G3;33;#3]WV*RMK;=U\F)4S^0JU12LMQ\\N7EO MH%,EABGB:.:-)(VZJZ@@_@:?13)3MJBA;Z)I-I*);;2[*"0='BMT4C\0*OT4 M4))%2G*;O)W(6M+9I_.:WB,H.=Y0;OSJ:BB@3;>Y0GT/2+J8S7&EV4TIZO); MHS'\2*N1Q1PQK'%&L<:C"JHP!^%/HI60W.4E9LRO$>L)H.@W6H-@O&N(U/\ M$YX4?G^F:XGX6:.[_:_$%UEI9F,<3-U/.7;\3Q^!KH_&6B0:[#:V]S/<1Q1L M7VQ,!N/3)R#TY_,UNZ78P:;I=K96RD0PQA5SU/N?<]:RMS5->AZL:BH9?:/Q ..5'J_)="W1116QY!__]D! end